Skip to main content
Fig. 2 | Journal of Patient-Reported Outcomes

Fig. 2

From: Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray

Fig. 2

ASPIRE II–mean change in QLDS score from baseline to Day 25 using MADRS as an anchor. Values are represented as mean ± 95% CI. MADRS was categorized as: severity criteria #1—no depression (score 0–12), slight depression (score 13–21), moderate depression (score 22–28), and severe depression (score > 28–60); severity criteria #2—no depression (score 0–6), mild depression (score 7–19), moderate depression (score 20–34), and severe depression (score > 34–60); and severity criteria #3—no depression (score 0–12), mild depression (score 13–17), moderate depression (score 18–34), and severe depression (score > 34–60). CAT Category, CI Confidence Interval, IMP Improvement, MADRS Montgomery–Åsberg Depression Rating Scale, QLDS Quality of Life in Depression Scale

Back to article page